Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > Forbes News CBD
View:
Post by TheeRook on Jul 17, 2020 2:43pm

Forbes News CBD

CBD For Coronavirus? New Study Adds Evidence For Cannabis As Covid-19 Treatment


Now new evidence is adding support to the theory that cannabis derived CBD may help those suffering from the severe lung inflammation that occurs in more serious cases of COVID-19. The study from researchers at Augusta University in Georgia suggests  that CBD may positively impact ARDS or acute respiratory distress syndrome – a dangerous symptom in COVID-19 caused by an overactive inflammatory response. This is sometimes referred to as a ‘cytokine storm’. The authors of the study explain that “currently, other than supportive measures, there is no definitive cure for ARDS, illustrating the urgent need for creative and effective therapeutic modalities to treat this complex condition.”






https://www.forbes.com/sites/emilyearlenbaugh/2020/07/15/cbd-for-coronavirus-new-study-adds-evidence-for-cannabis-as-covid-19-treatment/amp/
Comment by GoTogether on Jul 17, 2020 5:40pm
Nice to know, but nothing new here for TBP's researchers, ... hurray ! According to Guy Chamberland they are already studying this kind of drug in animals for over 10 years now > to prevent / to reduce the severe inflammation responsible for the 'cytokine storm’. They have a lot of knowledge about it. He confirms this in the interview, beginning around the @1.40 mark in ...more  
Comment by Mymoneyisyourmo on Jul 18, 2020 12:07am
Yes this is the real advantage Tetra has over the competition. Most companies are starting from scratch trying to develop something for COVID. Tetra's ARDS is already 10 years in the making!! In my opinion with this amount of extensive research, and the fact that Tetra's toxicology studies have already been completed and DID NOT show any disproportionate or human specific metabolite, I ...more  
Comment by Mymoneyisyourmo on Jul 18, 2020 12:10am
I don't think you folks realize the significance of this.
Comment by RockThunder on Jul 18, 2020 10:39am
I think tetra should focus on 1 or 2 things spcificly the one that gone a genarate money  we all been here waiting for years , i think they should put all their energy on the product they want to put on the market asap so shareoolders ,, will be less in doubt and we can stop waiting to see a unicorn
Comment by Mymoneyisyourmo on Jul 19, 2020 11:00pm
That's exactly what they ARE doing with ARDS and Awaye
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities